Breaking News: TRASTUZUMAB deruxtecán Shows Significant Survival Benefits in Gastric Cancer
Latest Clinical Trial Results Present a New Hope for Advanced Gastric Cancer Patients
In a significant development for patients with Her2 positive gastric cancer, the Phase III clinical trial Destiny-Gastric04 has demonstrated that TRASTUZUMAB deruxtecán offers a substantial improvement in overall survival (OS) compared to the combination of RAMCUC образом PACLTAXEL. These groundbreaking findings were presented at the ongoing Annual Congress of the American Society of Clinical Oncology (ASCO) 2025. The data have also been published in the prestigious journal “The New England Journal of Medicine.”
Key Findings from the Trial
The novel ADC (Antibody-Drug Conjugate) designed by Daiichi Sankyo, using their proprietary DXD technology, shows a notable 30% reduction in the risk of death in comparison to the combination therapy. The median overall survival with TRASTUZUMAB deruxtecán was 14.7 months, versus 11.4 months with RAMCUC образом PACLTAXEL. Additionally, the progression-free survival (PFS) improved by 26%, with a median PFS of 6.7 months for the ADC compared to 5.6 months for the combination therapy.
Expert Insights and Clinical Implications
“Gastric cancer is particularly difficult to treat, especially in the advanced stages,” stated Dr. Kohei Shitara, the Principal Investigator of the Destiny-Gastric04 study. “The superior overall survival demonstrated in this trial confirms that our ADC could become the second-line treatment standard for gastric cancer.” This breakthrough offers real hope for advanced gastric cancer patients who traditionally faced dismal outcomes after first-line treatments.
Understanding the ADC and Its Development
The development and marketing of TRASTUZUMAB deruxtecán are a joint effort between Daiichi Sankyo and AstraZeneca. Dr. Ken Takeshita of Daiichi Sankyo highlighted, “This is the first time a therapy aimed at Her2 has demonstrated a survival benefit in a Phase III randomized trial for second-line treatment of gastric cancer.” The ADC is currently approved in over 70 countries for the treatment of metastatic gastric cancer as a second or third-line therapy, based on earlier trials.
Future Directions and Further Trials
The promising results from the Destiny-Gastric04 study have sparked further investigations into the potential of this ADC in earlier stages of gastric cancer. Both companies are now pursuing Phase III studies to evaluate this innovative therapy as a first-line treatment in combination regimens for HER2 positive patients with metastatic disease.
Implications for Clinical Practice
These findings will likely influence clinical practice, offering physicians a more effective treatment option for patients with metastatic gastric cancer. Furthermore, the drug’s robust safety profile, consistent with previous trials, adds to its appeal for widespread adoption.
Stay Updated with the Latest in Oncology Research
For more breaking news and insights from the world of oncology, keep following archyde.com. We bring you the latest research, expert opinions, and practical advice to stay ahead in the ever-evolving landscape of cancer treatment.
